Visit https://losingweightrx.com to get started.

Educational content only — not medical advice. Talk to a licensed clinician before starting any medication. Telehealth FX is an informational and affiliate platform, not a medical provider or pharmacy, and may earn a commission. Compounded medications are not FDA-approved. Individual results vary.

In this episode we look at what the science actually says about how well GLP-1 medications work for weight management — and what "effective" really means once you look past the first few months. We cover how semaglutide and tirzepatide work, the headline results from the major clinical trials, the newly approved any-time-of-day GLP-1 pill, the cardiovascular findings that go beyond the scale, and the honest catch most ads skip: these medications work while you take them, and much of the lost weight tends to return after stopping.

Key facts: In the STEP 1 trial, average weight loss with semaglutide 2.4 mg was about 14.9% over 68 weeks. In SURMOUNT-1, tirzepatide produced roughly 16–22% average loss depending on dose. In the SELECT trial, semaglutide was linked to about a 20% reduction in major cardiovascular events in people with overweight/obesity and established heart disease. The newly approved oral GLP-1 showed up to about 12.4% weight loss at its highest dose over 72 weeks. Across follow-up studies, people regained roughly two-thirds of lost weight within a year of stopping.

Real risks discussed: gastrointestinal side effects; a boxed warning for thyroid C-cell tumors (not for those with a personal/family history of medullary thyroid carcinoma or MEN2); pancreatitis and gallbladder risks; and an eye-condition signal still under study.

Important: Compounded semaglutide and tirzepatide are not FDA-approved — the FDA does not evaluate them for safety, effectiveness, or quality — and they are not the same as branded Ozempic, Wegovy, Mounjaro, or Zepbound. Prescription medications require evaluation and a prescription from a licensed clinician, and eligibility is individual. Individual results vary.

Learn more or see if you may qualify at https://telehealthfx.com

#GLP1 #Semaglutide #Tirzepatide #WeightManagement #ObesityMedicine #HealthEducation #Telehealth